By Gabriel Paijo 
The landscape of oncology is shifting as new evidence from South America provides a granular look at the mechanisms behind one of the world’s most lethal malignancies. A landmark study conducted by Brazilian researchers and published in the prestigious journal Molecular and Cellular Endocrinology has uncovered how pancreatic cancer manages to spread during its earliest stages, long before clinical symptoms often appear. By identifying a specific protein called periostin and its interaction with pancreatic stellate cells, the research team has mapped the biological "roadway" that cancer cells use to invade nearby nerves. This process, known as perineural invasion, is a critical driver of metastasis and serves as a primary indicator of the disease’s aggressive nature. The findings not only offer a clearer understanding of the tumor microenvironment but also point toward a new frontier in precision medicine, where treatments could be tailored to block these specific cellular pathways.
The Biological Mechanics of Early Invasion
Pancreatic ductal adenocarcinoma (PDAC), which accounts for approximately 90% of all pancreatic cancer cases, is notorious for its ability to evade early detection. For decades, scientists have sought to understand why this specific cancer is so adept at spreading to distant organs. The Brazilian study suggests the answer lies not just within the cancer cells themselves, but in how they manipulate their surroundings.
The research team found that pancreatic tumors do not exist in isolation; they actively "reprogram" the healthy tissue surrounding them. This surrounding environment, known as the stroma, was previously thought to be a passive structural support system. However, the study reveals that the stroma is a highly active participant in cancer progression. Within this environment, pancreatic stellate cells—specialized cells that usually maintain the organ’s structure—are hijacked by the tumor. Once activated, these cells produce high levels of periostin, a protein that plays a central role in remodeling the extracellular matrix.
The extracellular matrix acts as the "glue" that keeps healthy cells organized. When periostin levels surge, this matrix undergoes a radical transformation. It becomes disrupted and porous, creating a path of least resistance for cancer cells. As these cells break away from the primary tumor, they utilize the remodeled matrix to reach nearby nerve bundles. Once the cancer reaches a nerve, the nerve serves as a conduit—a literal highway—that transports malignant cells to other parts of the body, facilitating rapid metastasis.
A Global Health Crisis: By the Numbers
The urgency of this research is underscored by the devastating statistics associated with pancreatic cancer. Unlike many other forms of cancer that have seen significant improvements in survival rates due to early screening and advanced therapies, pancreatic cancer remains an outlier.
Globally, the disease is responsible for roughly 510,000 new diagnoses annually. Alarmingly, the annual death toll nearly matches the diagnosis rate, with approximately 500,000 deaths reported each year. This 1:1 ratio of incidence to mortality makes it one of the deadliest diseases in modern medicine. In Brazil, the National Cancer Institute (INCA) estimates approximately 11,000 new cases and 13,000 deaths annually, highlighting a significant public health burden where mortality often outpaces new diagnoses due to late-stage detection.
Dr. Pedro Luiz Serrano Uson Junior, an oncologist and one of the study’s authors, emphasizes the gravity of the situation. "It is an exceptionally aggressive cancer that is difficult to treat. Only about 10% of patients have a chance of long-term survival, defined as five years post-diagnosis," Uson noted. The primary reason for this low survival rate is that by the time a patient presents symptoms—such as jaundice, weight loss, or abdominal pain—the cancer has often already completed its perineural invasion and begun its journey to other organs.
Advanced Methodology: Mapping the Tumor Microenvironment
The study was a collaborative effort involving several of Brazil’s top scientific institutions. The work was centered at the Center for Research on Inflammatory Diseases (CRID), a Research, Innovation, and Dissemination Center (RIDC) funded by the São Paulo Research Foundation (FAPESP). The research was led by Carlos Alberto de Carvalho Fraga, with Helder Nakaya, a senior researcher at Einstein Israelite Hospital and professor at the University of São Paulo, serving as the principal investigator.
To achieve these results, the team utilized cutting-edge transcriptomics and spatial analysis tools. By analyzing 24 distinct pancreatic cancer samples, the researchers were able to observe the activity of thousands of genes at the individual cell level. This high-resolution approach allowed them to map the exact locations of different cell types within the tumor tissue and see how they interacted in real-time.
"We were able to integrate data from dozens of samples with extremely powerful resolution," said Nakaya. This level of detail was necessary to distinguish between the behavior of healthy cells and those that had been co-opted by the tumor. The study also leveraged large-scale public genomic databases, allowing the researchers to validate their findings against a broader set of international data. This "big data" approach enabled them to identify patterns that previous studies, focused on smaller or less diverse datasets, might have missed.
The Desmoplastic Reaction: The Tumor’s Fortress
One of the most significant challenges in treating pancreatic cancer is what researchers call the "desmoplastic reaction." As the tumor grows and the stellate cells produce periostin and other proteins, the area around the tumor becomes increasingly dense and fibrous. This creates a physical barrier—a hardened shell of tissue—that is highly inflamed and poorly vascularized.
This fibrous shield serves two purposes for the cancer: it protects the malignant cells from the body’s immune system and acts as a barrier against medical intervention. "The hardened tissue makes it significantly harder for chemotherapy and immunotherapy drugs to penetrate the tumor," Uson explained. This explains why many patients who receive standard-of-care treatments show little to no response; the drugs simply cannot reach the target cells in high enough concentrations to be effective.
By understanding that periostin is a key architect of this fibrous shield, researchers believe they have found a potential "weak point" in the tumor’s defenses. If the production of periostin can be inhibited, the desmoplastic reaction might be lessened, making the tumor more susceptible to existing chemotherapy and immunotherapy drugs.
Perineural Invasion as a Prognostic Marker
The study places a heavy emphasis on perineural invasion (PNI) as a marker of clinical outcomes. Because nerves are a direct link between different regions of the body, PNI is often the first step in systemic spread. Furthermore, because nerves are highly sensitive, this invasion is a primary cause of the debilitating pain associated with advanced pancreatic cancer.
Currently, PNI is a "hidden" factor in many diagnoses. "Unfortunately, we often discover this perineural invasion only after it’s already occurred," said Uson. "It’s typically seen in the surgical specimen when it goes for biopsy after the tumor has been removed." The research suggests that if clinicians could identify the molecular signatures of PNI—such as high periostin activity—earlier in the diagnostic process, they could better predict the aggressiveness of the tumor and adjust treatment plans accordingly.
Statistics indicate that more than 50% of pancreatic cancer cases involve PNI at the time of initial surgery. For these patients, the risk of recurrence is significantly higher, even if the primary tumor is successfully removed. This underscores the need for systemic therapies that can address microscopic spread along the nerve pathways.
The Future of Treatment: Precision Medicine and Targeted Antibodies
The ultimate goal of the Brazilian research team is to translate these molecular insights into clinical therapies. Periostin has emerged as a high-priority target for drug development. The researchers suggest that by developing antibodies designed to block periostin or by finding ways to deactivate the stellate cells that produce it, they could effectively "cut off the road" the cancer uses to spread.
This approach aligns with the global shift toward precision medicine, where treatments are designed based on the specific molecular and genetic profile of a patient’s tumor rather than a one-size-fits-all approach based on the organ of origin. "If we can develop antibodies or drugs that block these stellate cells, we’ll have tools to prevent the tumor from acquiring this invasive capacity so early," Uson noted.
Interestingly, clinical trials are already underway in other fields of oncology, such as breast and intestinal cancer, to test antibodies that target periostin. The success of these trials could pave the way for rapid adaptation to pancreatic cancer treatment. Because the mechanisms of tissue remodeling and nerve invasion are similar across various types of aggressive cancers, a breakthrough in one could have a "domino effect," benefiting a wide range of patients.
Conclusion and Next Steps
The study from the Center for Research on Inflammatory Diseases marks a significant step forward in the fight against a disease that has long been considered untreatable. By shifting the focus from the cancer cells themselves to the surrounding stroma and the role of periostin, the researchers have opened a new door for therapeutic intervention.
The next phase of the research will involve laboratory testing of specific inhibitors to see if the interruption of the periostin pathway can successfully halt nerve invasion in vivo. Additionally, the team plans to continue mining public genomic data to identify other proteins that might work in tandem with periostin to facilitate metastasis.
As precision medicine continues to advance, the hope is that pancreatic cancer will eventually be managed not as a death sentence, but as a treatable condition. "In the future, we’ll treat patients based on genomic and molecular changes rather than tumor type specifically," Uson concluded. "This is a significant advance in oncology that brings us closer to that goal."